Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by chrispion Jul 09, 2021 11:09am
110 Views
Post# 33521103

RE:RE:New article

RE:RE:New article
MineDigger wrote:
but no need to wate time clicking as no further info is provided, the article is just a rewrite of the MS NR.

Please Chrispi, evryone here knows everything in that article, we've got better things to do than reread the same information.



And that article https://themarketherald.ca/bioasis-announces-positive-results-from-an-efficacy-study-of-xb3tm-il-1ra-in-a-model-of-multiple-sclerosis-2021-07-07/ , although not giving additional scientific data, does an excellent job of summarizing the original press release, offering background info about the company and study that was not in the PR, and doing it in an easy-to-understand way for non-biotech people.
For those with no or little biotech background, I think the article gives a great perspective on the study!

Thanks for your great and helpful insight MD - did you even read the article?
<< Previous
Bullboard Posts
Next >>